Cathy A Rasmussen1, B Lynn Allen-Hoffmann2. 1. Department of Pathology and Laboratory Medicine, University of Wisconsin , Madison, Wisconsin. 2. Department of Pathology and Laboratory Medicine, University of Wisconsin , Madison, Wisconsin. ; Department of Surgery, University of Wisconsin , Madison, Wisconsin.
Abstract
BACKGROUND: For patients suffering from catastrophic burns, few treatment options are available. Chimeric coculture of patient-derived autologous cells with a "carrier" cell source of allogeneic keratinocytes has been proposed as a means to address the complex clinical problem of severe skin loss. THE PROBLEM: Currently, autologous keratinocytes are harvested, cultured, and expanded to form graftable epidermal sheets. However, epidermal sheets are thin, are extremely fragile, and do not possess barrier function, which only develops as skin stratifies and matures. Grafting is typically delayed for up to 4 weeks to propagate a sufficient quantity of the patient's cells for application to wound sites. BASIC/CLINICAL SCIENCE ADVANCES: Fully stratified chimeric bioengineered skin substitutes could not only provide immediate wound coverage and restore barrier function, but would simultaneously deliver autologous keratinocytes to wounds. The ideal allogeneic cell source for this application would be an abundant supply of clinically evaluated, nontumorigenic, pathogen-free, human keratinocytes. To evaluate this potential cell-based therapy, mixed populations of a green fluorescent protein-labeled neonatal human keratinocyte cell line (NIKS) and unlabeled primary keratinocytes were used to model the allogeneic and autologous components of chimeric monolayer and organotypic cultures. CLINICAL CARE RELEVANCE: Relatively few autologous keratinocytes may be required to produce fully stratified chimeric skin substitute tissue substantially composed of autologous keratinocyte-derived regions. The need for few autologous cells interspersed within an allogeneic "carrier" cell population may decrease cell expansion time, reducing the time to patient application. CONCLUSION: This study provides proof of concept for utilizing NIKS keratinocytes as the allogeneic carrier for the generation of bioengineered chimeric skin substitute tissues capable of providing immediate wound coverage while simultaneously supplying autologous human cells for tissue regeneration.
BACKGROUND: For patients suffering from catastrophic burns, few treatment options are available. Chimeric coculture of patient-derived autologous cells with a "carrier" cell source of allogeneic keratinocytes has been proposed as a means to address the complex clinical problem of severe skin loss. THE PROBLEM: Currently, autologous keratinocytes are harvested, cultured, and expanded to form graftable epidermal sheets. However, epidermal sheets are thin, are extremely fragile, and do not possess barrier function, which only develops as skin stratifies and matures. Grafting is typically delayed for up to 4 weeks to propagate a sufficient quantity of the patient's cells for application to wound sites. BASIC/CLINICAL SCIENCE ADVANCES: Fully stratified chimeric bioengineered skin substitutes could not only provide immediate wound coverage and restore barrier function, but would simultaneously deliver autologous keratinocytes to wounds. The ideal allogeneic cell source for this application would be an abundant supply of clinically evaluated, nontumorigenic, pathogen-free, human keratinocytes. To evaluate this potential cell-based therapy, mixed populations of a green fluorescent protein-labeled neonatal human keratinocyte cell line (NIKS) and unlabeled primary keratinocytes were used to model the allogeneic and autologous components of chimeric monolayer and organotypic cultures. CLINICAL CARE RELEVANCE: Relatively few autologous keratinocytes may be required to produce fully stratified chimeric skin substitute tissue substantially composed of autologous keratinocyte-derived regions. The need for few autologous cells interspersed within an allogeneic "carrier" cell population may decrease cell expansion time, reducing the time to patient application. CONCLUSION: This study provides proof of concept for utilizing NIKS keratinocytes as the allogeneic carrier for the generation of bioengineered chimeric skin substitute tissues capable of providing immediate wound coverage while simultaneously supplying autologous human cells for tissue regeneration.
Authors: B L Allen-Hoffmann; S J Schlosser; C A Ivarie; C A Sattler; L F Meisner; S L O'Connor Journal: J Invest Dermatol Date: 2000-03 Impact factor: 8.551
Authors: Barbara A Latenser; Sidney F Miller; Palmer Q Bessey; Susan M Browning; Daniel M Caruso; Manuel Gomez; James C Jeng; John A Krichbaum; Christopher W Lentz; Jeffrey R Saffle; Michael J Schurr; David G Greenhalgh; Richard J Kagan Journal: J Burn Care Res Date: 2007 Sep-Oct Impact factor: 1.845
Authors: Michael J Schurr; Kevin N Foster; John M Centanni; Allen R Comer; April Wicks; Angela L Gibson; Christina L Thomas-Virnig; Sandy J Schlosser; Lee D Faucher; Mary A Lokuta; B Lynn Allen-Hoffmann Journal: J Trauma Date: 2009-03